Literature DB >> 31844038

Polymorphisms of the TNF Gene and Three Susceptibility Loci Are Associated with Crohn's Disease and Perianal Fistula Crohn's Disease: A Study among the Han Population from South China.

Min Zhang1,2, Xiaoyan Wang2,3, Xiaodong Jiang1,2, Xiangling Yang2,3, Chuangyu Wen2,3, Min Zhi1,2, Xiang Gao1,2, Pinjin Hu1,2, Huanliang Liu2,3.   

Abstract

BACKGROUND Although 90 susceptibility loci of Crohn's disease (CD) have been confirmed in the Asian population, susceptibility genes for perianal fistula of CD (pCD) in this population remain unknown. This study explored susceptibility genes for CD and pCD in the Han population from South China. MATERIAL AND METHODS In total, 490 patients diagnosed with CD between July 2012 and June 2016 at the Sixth Affiliated Hospital of Sun Yat-sen University were included and divided into the CD group (n=240) and the pCD group (n=250). The healthy control group was composed of 260 volunteers. Peripheral blood samples were taken, and single nucleotide polymorphism (SNP) locus sequencing was used to screen for susceptibility loci. SNPs were sequenced using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. RESULTS Nine SNPs in TNFSF1 on chromosome 9 were associated with CD. Among them, the rs6478106 locus is a risk locus for CD. The distribution frequency of the T allele of the rs6478106 SNP was significantly different between cases and controls (32.49% versus 18.27%, P<0.001). Rs72553867, located in the IRGM gene on chromosome 5, rs4409764, located in the NKX2-3 gene on chromosome 10, and rs3731772, located in the AOX1 gene on chromosome 2, were susceptibility factors for pCD. Nine SNPs located in TNFSF15 on chromosome 9 were related to CD in Han individuals from Southern China. CONCLUSIONS The rs6478106 T allele is associated with the risk of CD in the investigated population. SNPs rs72553867 (IRGM gene), rs4409764 (NKX2-3 gene), and rs3731772 (AOX1 gene) increase the risk of pCD.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31844038      PMCID: PMC6929548          DOI: 10.12659/MSM.917244

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


Background

Crohn’s disease (CD) is a major component of chronic idiopathic inflammatory disease, which primarily affects the terminal ileum and colon. A prospective, population-based study showed that the incidence rate for CD was as high as 1.09 per 100 000 person-years in China [1]. Although the CD prevalence in China is still lower than that in Western countries, this figure has increased rapidly over the past few decades [2]. The underlying etiology of CD is still undetermined [3], but it has long been thought as a consequence of an inappropriate mucosal immune response to antigenic stimulation from the gut microbiota in a genetically susceptible host [4]. Studies from twins suggested an approximately 50% genetic contribution in CD [5]. Therefore, the identification of the related genetic changes that are implicated in CD susceptibility would provide insights into the etiology of this disorder. To the best of our knowledge, over 200 single nucleotide polymorphisms (SNPs) in several genes (such as NOD2/CARD15, NOD1/CARD4, and ABCB1) are related to CD in Western populations [6-9]. However, due to genetic differences, some SNPs failed to show a link to CD in the Asian population [10,11]. For example, mutations within genes from the NOD2/CARD15, ATG16L1, and IL23/Th17 signaling pathways were demonstrated to confer susceptibility to CD only in Western patients and not in Chinese and Japanese patients [12-15]. In addition, studies in the Asian population have revealed some unique SNPs, e.g., c.374T>C of the DLG1 gene in Chinese patients [16], ATG16L2 and/or FCHSD2 in Chinese and South Korean patients [17,18], and SNPs in the TNFSF15 gene in East Asians [19]. These differences emphasize the importance of identifying population-specific gene variants. Perianal fistula CD (pCD) is a subtype of CD with poor prognosis and low quality of life. According to population-based studies, the proportion of pCD ranges from 12% to 40% among CD patients, and this prevalence varies according to disease location and disease duration [20]. A European project has revealed that perianal fistula formation in CD patients might be attributed to genes including IL23R, LOC441108, PRDM1, and NOD2 [21]. Another study in the Italian population suggested an association of the SNP rs4958847 in the IRGM gene with the susceptibility to pCD [22]. Studies in Dutch, German, and Norwegian populations found an association between rs2165047 in the DLG5 gene and the NOD2 haplotype with perianal development [23,24]. Furthermore, rs72796353 in NOD2 was also reported to be significantly associated with perianal fistula development in cases devoid of SNPs rs2066844, rs2066845, and rs2066847 [25]. Among the Asian population, only 2 studies have screened potentially pathogenic SNPs in CD patients and explored their associations with perianal fistula formation. One recent study was conducted in a Japanese population and found that the AT haplotype in the TNFRSF1B gene might promote fistula development [26], while another study in a Korean population revealed the association of the rs4574921 CC genotype within the TNFSF15 gene with perianal fistula formation [27]. However, susceptibility genes and SNPs have never been assessed in the Chinese population. In addition, to reveal the unique gene variants predisposing patients to pCD, it is important to identify the differences in susceptibility genes and SNPs between non-perianal CD (npCD) patients and pCD patients, which have yet to be evaluated. Here, we extended previous findings in the Asian population by assessing the association between the CD susceptibility loci reported in Asians to Southern Chinese CD patients to clarify the specificity of CD susceptibility genes in the Chinese population and further compare the frequencies of those loci between pCD and npCD patients to explore the SNPs conferring susceptibility to pCD in the Chinese population.

Material and Methods

Patients

In total, data pertaining to 490 CD patients diagnosed between July 2012 and June 2016 were collected from the Inflammatory Bowel Disease (IBD) Center in the Sixth Affiliated Hospital of Sun Yat-sen University, including 250 patients with perianal fistula and 240 with non-perianal fistula. The CD diagnostic criteria were based on the Expert Consensus Document of IBD diagnosis and treatment in China, 2012 [28]. Demographic and clinical information, such as age, sex, race, year of diagnosis, disease location and disease behavior, were collected from all patients. CD behavior includes B1 (non-stricturing, non-penetrating), B2 (stricturing), and B3 (penetrating). In total, 260 healthy volunteers were also recruited from Guangzhou Blood Center. All included patients and controls were of Han ethnicity and were born in Southern China, including the provinces of Guangdong, Guangxi, Fujian, Jiangxi, Jiangsu, Zhejiang, Hunan, Hubei, Sichuan, Chongqing, Yunnan, Hainan, Taiwan, Hongkong, and Macao. This study obtained approval from the institutional Review Board of the Sixth Affiliated Hospital, Sun Yat-sen University (IRB number: 2017ZSLYEC-017). Written informed consent was obtained from each participant.

Sample collection

Approximately 2 mL of peripheral venous blood was taken from each patient after fasting. The blood sample was centrifuged at 1000 rpm for 10 minutes. After serum removal, the sample was stored at −80°C.

Candidate locus determination

We searched the MEDLINE, EMBASE and China National Knowledge Infrastructure (CNKI) databases to identify studies reporting the candidate loci and genes implicated in Asian CD patients. Finally, 90 loci were identified as risk loci candidates for screening among CD patients (Supplementary Table 1).

DNA extraction

DNA was extracted from the peripheral blood leucocytes by standard procedures with a Blood Genomic DNA Isolation Kit (Tiangen, Beijing, China; batch no., DP335). The DNA concentration was determined and then the sample was stored at −20°C.

SNP locus sequencing

Genotyping was performed with matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) [29] on the MassARRAY platform (BGI Tech, Beijing, China). A 4-μL reaction system consisted of PCR buffer with 1.5 mM MgCl2 (0.625 μL), 25 mM MgCl2 (0.325 μL), 25 mM dNTPs (0.1 μL), 500 nM Primer Mix (1.0 μL), 5 U/μL HotStar Taq (0.1 μL), and HPLC grade water (1.85 μL). The system was applied to a 384-well plate. Template DNA at 20 ng/μL (1 μL) was added, and a 1-minute centrifugation at 1000 rpm was performed. The amplification conditions included 94°C for 5 minutes, followed by 45 cycles of 94°C for 20 seconds, 56°C for 30 seconds, 72°C for 1 minute, and 72°C for 3 minutes, with a final holding at 4°C. Shrimp alkaline phosphatase (SAP) mix at 2.0 μL was prepared, which contained 1.53 μL of HPLC grade water, 0.17 μL of SAP buffer (10x), and 0.3 μL of SAP enzyme (1 U/μL). Excess dNTPs were removed from the reaction system by incubating 5 μL of the reaction with the SAP mix at 37°C for 20 minutes followed by incubating it at 85°C for 5 minutes and then at 4°C until used. Single-based extension liquid was prepared in a final volume of 2 μL, containing 0.2 μL of iPLEX Buffer Plus (0.222×), 0.2 μL of iPLEX Termination Mix (1×), 0.94 μL of Primer Mix (7 μM: 14 μM), and 0.619 μL of HPLC grade water. The liquid was used to produce 9 μL of the single-based extension reaction system. The system was subsequently subjected to 40 cycles of 94°C for 30 seconds and 94°C for 5 seconds, 5 cycles of 52°C for 5 seconds, 45 cycles of 80°C for 5 seconds and 72°C for 3 minutes, and a final holding step at 4°C. Resin purification was performed. After centrifugation, the products were sampled onto a 384-well SpectroChip (Sequenom, USA) for MALDI-TOF MS. The obtained data were analyzed with TYPER4.0.

Statistical analysis

All analyses were performed with SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). Comparisons of characteristics among cases with and without perianal fistula and controls were made with one-way analysis of variance (ANOVA) or the chi-squared test whichever applicable; post hoc multiple comparisons were performed by Bonferroni correction analyses. Assessment of the genetic equilibrium of two comparison sets (CD patients versus controls; CD patients with or without perianal fistula) was made using the Hardy-Weinberg equilibrium test. Genotype frequency comparisons between the aforementioned sets were performed with the chi-squared test and are presented as odds ratios (ORs) and 95% confidence intervals (CIs). Haploview 4.2 was utilized for the linkage disequilibrium analysis. All tests were 2-sided, and P<0.05 was considered significant. The genome-wide association study (GWAS) involved statistical comparisons of hundreds of thousands of SNPs. To maintain a significance level of 0.05, the level of inspection for each comparison must be controlled to a certain extent, and we set a significance level for SNP comparisons at P<10−7.

Results

Characteristics

Generally, CD patients were older than the controls. The patients with pCD were older than those with npCD (Table 1). The majority of cases were male in all 3 groups. In addition, higher percentages of patients with npCD than of those with pCD were single and had penetrating CD.
Table 1

Clinical characteristics of CD patients and healthy controls.

CharacteristicsCD with perianal fistula (n=250)CD without perianal fistula (n=240)Controls (n=260)F/χ2 valueP value
Age (years)32.61±13.3228.51±9.7224.34±3.9652.66<0.001
Male (n, %)156 (62.4)186 (77.5)174 (66.9)12.9310.002
Location (n, %)2.720.26
 Ileal±upper17 (6.8)26 (10.8)NA
 Colonic±upper26 (10.4)27 (11.3)NA
 Ileocolonic±upper207 (82.8)187 (77.9)NA
Behavior (n, %)58.956<0.001
 B163 (25.2)35 (14.6)NA
 B272 (28.8)39 (16.3)NA
 B3115 (46.0)176 (73.3)NA

CD – Crohn’s disease; B1 – non-stricturing, non-penetrating; B2 – structuring; B3 – penetrating; NA – not applicable.

Risk genetic loci screening

In total, 90 genetic loci among 750 patients were identified (Supplementary Table 1). SNPs satisfying a detection rate >90%, MAF >5 and Hardy-Weinberg equilibrium were further screened, and 70 were obtained for further analysis (Supplementary Table 2).

Correlation analysis of genotypes in CD patients

Single SNP association analysis

The frequency comparison between risk loci in CD patients and controls (Supplementary Table 3) indicated that 9 SNPs (rs10114470, rs3810936, rs6478109, rs6478108, rs4263839, rs7848647, rs4246905, rs457492, and rs6478106) were significantly related to CD (all with P<10−7 in Bonferroni multiplex analysis; Table 2). Among those SNPs, 5 were C>T mutations, 2 were G>A mutations, and the remaining 2 were T>C mutations. All those variants were located in the TNFSF15 gene on chromosome 9. Rs6478106 was the only SNP that presented correlation with the pathogenicity of CD (OR=2.15, 95% CI 1.94–3.26), while the remaining SNP exhibited protective roles against CD.
Table 2

CD-related SNPs.

Chromosome no.dbSNPGeneMajor alleleRisk alleleFrequency among CD groupFrequency among controlsAllelic test P-valueOR95% CI
9rs10114470TNFSF15CT0.2830.5661.41E-110.477(0.385, 0.593)
9rs3810936TNFSF15CT0.3830.5652.40E-110.477(0.384, 0.594)
9rs6478109TNFSF15GA0.3700.5393.55E-100.504(0.406, 0.625)
9rs6478108TNFSF15TC0.2740.5433.71E-100.504(0.406, 0.625)
9rs4263839TNFSF15GA0.3730.5415.08E-100.506(0.407, 0.628)
9rs7848647TNFSF15CT0.3710.5395.11E-100.506(0.408, 0.628)
9rs4246905TNFSF15CT0.2650.4291.18E-090.499(0.398, 0.625)
9rs457492TNFSF15TC0.2660.4191.55E-090.502(0.400, 0.628)
9rs6478106TNFSF15CT0.3250.1834.29E-092.153(1.939, 3.257)
We further assessed the genotype distribution of rs6478106 among different age and gender groups. The results indicated that there were no associations of rs6478106 with age (≤30 vs. >30, χ2=0.386, P=0.824) or sex (male versus female, χ2=2.096, P=0.351) (Table 3).
Table 3

Distribution of rs6478106 genotypes in different ages and sexes.

Genotypes (n)χ2P value
CCCTTT
Age (years)≤30112106240.3860.824
>3010811525
SexMale7764142.0960.351
Female14315735

Haplotype analysis

Five SNPs (rs4574921, rs6478106, rs10114470, rs3810936, and rs4246905) were found in a 14-kb linkage disequilibrium region (block 1) on chromosome 9, while another 5 SNPs (rs4263839, rs6478108, rs6478109, rs7865494, and rs7848647) were found in a 17-kb linkage disequilibrium region (block 2) on chromosome 9. Haploview analysis showed that the haplotypes CCTTT, TTCCC, CCTCT and TCCTC in block 1 significantly increased the risk of CD (P<0.05).

Correlation analysis between genotype distribution and perianal fistula of CD

Correlation analysis between single SNP and perianal fistula of CD

The comparison analysis between pCD and npCD patients (Supplementary Table 4) indicated that rs72553867, rs4958847, rs4409764, rs888208, rs3731772, and rs1292053 were candidate SNPs for susceptibility to CD perianal fistula (adjusted P<0.05, according to the Bonferroni test). Rs72553867, rs4958847, rs4409764, rs888208, rs3731772, and rs1292053 are located on chromosomes 5, 5, 10, 2, and 17, respectively. Among these candidates, rs72553867 (OR=1.685, 95% CI 1.188–2.390) and rs4958847 (OR=1.365, 95% CI 1.047–1.778) were found to be located in an IRGM coding region on chromosome 5. Rs4409764 (OR=1.329, 95 CI% 1.033–1.709) and rs888208 (OR=1.338, 95% CI 1.032–1.735) were found to be located in the NKX2–3 gene. Rs3731772 is in the AOX1 gene (OR=1.335, 95% CI 1.025–1.740), and rs1292053 was in the coding region of TUBD1 (OR=1.300, 95% CI 1.010–1.674) (Table 4).
Table 4

Perianal fistula of CD-associated SNP loci.

NameChr. noGene or locusMajor/minor alleleRisk allelepCD group RAFCD group RAFOR (95% CI)P allele
rs72553867chr5IRGMC/AA0.1940.1251.685 (1.188–2.390)0.003
rs4958847chr5IRGMA/GA0.6880.6171.365 (1.047–1.778)0.021
rs4409764chr10NKX2–3G/TT0.5580.4871.329 (1.033–1.709)0.027
rs888208chr10NKX2–3A/GA0.6560.5881.338 (1.032–1.735)0.028
rs3731772chr2AOX1T/CT0.6810.6151.335 (1.025–1.740)0.032
rs1292053chr17TUBD1G/AA0.4820.4171.300 (1.010–1.674)0.041

Chr. – chromosome; RAF – risk allele frequency.

Adjusted analysis between single SNPs and perianal fistula of CD

We further added age and gender as covariates to the analysis (Supplementary Table 5) and found that rs72553867 located in the IRGM gene on chromosome 5 (OR=1.770, 95% CI 1.151–2.723), rs4409764 located in the NKX2–3 gene on chromosome 10 (OR=1.886, 95% CI 1.181–3.012) and rs3731772 located in the AOX1 gene on chromosome 2 (OR=2.131, 95% CI 1.150–3.949) were SNPs that conferred susceptibility to pCD.

Haplotype analysis

Haplotype analysis revealed a 54-kb monomer block in chromosome 5 that contained 4 haplotypes, namely, CTCTAG, TCCCGA, TCACAA, and CTCTAA. Compared with the CTCTAG and CTCTAA haplotypes, haplotypes TCCCGA and TCACAA were associated with pCD (P<0.05).

Discussion

This study showed that 9 SNPs (rs10114470, rs3810936, rs6478109, rs6478108, rs4263839, rs7848647, rs4246905, rs4574921, and rs6478106) located in TNFSF15 on chromosome 9 are related to CD in the Han population from Southern China. Rs6478106 is the only risk SNP associated with CD. Further analysis revealed that rs72553867 (located in IRGM on chromosome 5), rs4409764 (located in NKX2–3 on chromosome 10) and rs3731772 (located in AOX1 on chromosome 2) increase the risk of pCD. TNFSF15 is mainly expressed in endothelial cells and can be induced in myeloid cells after the ligation of TLR and FcR by IgG ICs and the co-stimulation of T cells through the receptor DR3 [30]. Studies have confirmed the upregulated mRNA and protein levels of TNFSF15 in macrophages and CD4+/CD8+ lymphocytes in the intestinal lamina propria of CD patients [31]. TNFSF15 can bind to death domain receptor 3 and provide co-stimulatory signals that activate lymphocytes, inducing IFN-γ secretion and prompting participation in inflammatory responses [32,33]. Therefore, excessive expression of TNFSF15 can initiate and aggravate mucosal inflammation in CD patients. In European populations, the association of the TNFSF15 polymorphism with CD susceptibility has been widely reported [34,35]. Rs4979462 and rs7848647 in TNFSF15 were reported to be related with CD in Korean and Japanese populations [18,27,36]. In China, only 1 study was conducted on the association between TNFSF15 and CD, and the authors found that the 3 SNPs in TNFSF15 (rs3810936, rs6478109, rs7848647) were not significantly associated with CD genetic susceptibility and clinical subtypes in the Han population [37], which contrasts with our results that found 9 SNPs (rs10114470, rs3810936, rs6478109, rs6478108, rs4263839, rs7848647, rs4246905, rs4574921, and rs6478106) in TNFSF15 were related to CD. However, this study had a small sample size (42 CD patients and 49 healthy), which might lead to a limited power to discover significant associations [37]. Consistent with the results in the Japanese population [38], our analyses also indicated that rs6478106 was a susceptibility SNP for CD. Our analysis further revealed that this association had no relationship with age or sex. Therefore, we propose that the genetic variation of TNFSF15, especially rs6478106T, is related to an increased risk for CD in China. The genetic variations of TNFSF15 in this study may provide evidence regarding the etiology of the disease and information that may be important for the development of treatments. IRGM is widely expressed in various human cells and plays an important regulatory role in intracellular pathogen-associated immunity. IFN-γ can induce the expression of the IRGM mouse homologue LRG-47 and produce auto lysosomes, while the lack of LRG-47 results in an increased susceptibility to infection [39]. The rs13361189 and rs4958847 loci of IRGM were confirmed to be related to CD susceptibility in a large-scale clinical trial [40]. An Italian study showed that the polymorphisms rs1000113 and rs4958847 in the autophagy gene IRGM might participate in the pathogenesis of CD and that the polymorphism of rs4958847 was related to fistula behavior [22]. Another study among the Korean population suggested that rs10065172 and rs72553867 are protective factors against the development of CD [41]. Although increasing efforts have been devoted to focusing on the associations of IRGM mutations with CD, research on CD susceptibility genes in the Han population remains limited. In the study conducted by Zheng et al., 318 CD patients were examined, but no association between the rs13361189 polymorphism in IRGM and CD was observed for the Chinese population [42], consistent with our result. We also found that in addition to rs4958847, the rs72553867 polymorphism was also closely related to the formation of perianal fistula in the Southern Han population. Our results suggested that IRGM gene polymorphisms might affect IRGM expression and thus alter the severity of intestinal mucositis. Previous studies indicated the genetic association of NKX2–3 with pCD. Yu et al. analyzed the mRNA expression and protein level of NKX2–3 in American patients with familial IBD and found a significant link of NKX2–3 to CD [43]. Another Japanese study also found that the rs10883365 polymorphism of NKX2–3 was positively correlated with CD [44]. In addition, a Korean study showed that the rs88208 locus in NKX2–3 was also associated with CD, whereas studies in the Chinese population had the opposite conclusion [45,46]. In the southern Han population, our study showed a significant relation between the rs4409764 and rs888208 sites of NKX2–3 and the pathogenesis of pCD. More noteworthy, this study also found that rs3731772 was significantly associated with pCD in the Han population in southern China. The results of our study may provide clues for the function of the AOX1 gene in patients with fistula CD. Our study suffered from several potential limitations. First, screening for selected candidate loci and genes instead of genome-wide sequencing might lead to missed pathogenic SNPs. However, the selection of our SNP pool was based on multiple related studies that were obtained through a systematic search in MEDLINE and 2 other comprehensive databases in China. Second, we did not perform functional genomics research in this study. Functional analysis is helpful in ascertaining the actual roles of those genes, and our analysis may lay the groundwork for further potential function analyses. Third, although this study is the first confirmative research on susceptibility loci associated with perianal fistula CD in the Chinese population, it is preliminary and suffers from a small sample size based on a single center. Thus, the results of this study need to be validated by future multicenter studies with a large sample.

Conclusions

In the Han population from South China, 9 SNPs in TNFSF15 are related to CD and 3 SNPs located in IRGM, NKX2–3, and AOX1 increase the risk of pCD. This study is the first confirmative study on susceptibility loci associated with perianal fistula CD in this population, and its results are helpful for the exploration of new disease-associated mechanisms in the future. Risk locus candidates for screening among CD patients. SNPs selected for analysis. Analysis results for 70 SNPs related to CD. SNPs are ordered according to P values. Chr – chromosome. Analysis results for SNPs related to pCD. SNPs are ordered according to P values. p value for the dominant model; p value for the regressive model; p value for the additive model. Chr – chromosome; RAF – risk allele frequency Logistic analysis results for SNPs related to pCD. Dominant model; additive model.
Supplementary Table 1

Risk locus candidates for screening among CD patients.

GeneSNPChrG-positionAlleleFunctional consequence
4p14rs1487630438335823C>TIntron variant
ATG16L1rs22418802234183368A>GMissense
ATG16L2rs112356041172533536C>TMissense
ATG16L2-FCHSD2rs112356671172863697A>G
BTNL2rs28362680632370816G>AIntron variant
CARD9rs2007354029139265120C>TMissense
CDKAL1rs6908425620728731T>CIntron variant
DEFB1rs297888086724306G>AUpstream variant 2KB
DNAH12rs4462937357414434A>GMissense
DR4rs13278062823082971G>TUpstream variant 2KB
DR4rs20575823059324C>GMissense
DR5rs1047266822900701G>AIntron variant
DLG1rs5278296473197194534A>GMissense
DLG1rs11349863197138371C>TMissense
FUT3rs28362459195844781A>CMissense
FUT3rs3745635195844332C>TMissense
FUT3rs3894326195843773A>TMissense
GPR35rs37491722241570249A>CMissense
HLA-DQA2rs3208181632713030T>CSynonymous codon
IL-23Rrs11209026167705958G>AMissense
IL-23Rrs6588248167652984T>GIntron variant
IL-23Rrs7517847167681669T>GIntron variant
IL-23Rrs1004819167670213G>AIntron variant
IL-23Rrs76418789167648596G>AMissense
IL-23Rrs11209032167740092G>A
IL-27rs1531091628507775T>CIntron variant
IRF5rs20046407128578301G>TIntron variant
IRF5rs38073067128580680G>TIntron variant
IRGMrs100651725150848436C>TSynonymous codon
IRGMrs117418615150898347A>GIntron variant
IRGMrs126540435150846533A>GUtr variant 5 prime
IRGMrs133611895150843825T>C
IRGMrs49588475150860025G>AIntron variant
IRGMrs725538675150848404C>AMissense
IRGMrs96378705150848053G>AUtr variant 5 prime
IRGMrs96378765150847863C>TUtr variant 5 prime
MHCrs7765379632680928T>G
MHCrs9271366632619077G>A
BTNL2rs10947261632405455G>TIntron variant
NFKBIArs22736501435870798C>TUtr variant 3 prime
NKX2–3rs1088336510101287764G>ANc transcript variant
NKX2–3rs440976410101284237T>G
NKX2–3rs88820810101284237T>G
NOTCH4rs422951632188383T>CMissense
PPP5Crs48023071946346549G>TUpstream variant 2KB
PTPN2rs5140001812854073C>TIntron variant
PUS10rs13003464261186829A>GIntron variant
PUS10rs7608910260977721A>GIntron variant
RNASET2rs21490856167371110T>CUpstream variant 2KB
SLC22A4rs10501525132340627C>TIntron variant
SLC25A15-ELF1-WBP4rs73291741341558110A>GIntron variant
SMNDC1-DUSP5rs1119512810112186148C>T
SOX11rs1189408125664008G>T
STAT3rs10530041740466092G>AUtr variant 3 prime
STAT3rs98911191740507980A>CIntron variant
STAT4rs75748652191964633T>GIntron variant
TBC1D1-KLF3rs6856616438325036T>C
TNF-αrs1799964631542308T>CDownstream variant 500B
TNF-αrs1800630631542476C>ADownstream variant 500B
TUBD1rs12920531759886176A>GIntron variant
TNFSF15rs101144709117547772T>CUtr variant 3 prime
TNFSF15rs38109369117552885T>CSynonymous codon
TNFSF15rs42638399117566440A>GIntron variant
TNFSF15rs45749219117538334C>T
TNFSF15rs64781069117545666C>T
TNFSF15rs64781089117558703C>TIntron variant
TNFSF15rs64781099117568766A>GUpstream variant 2KB
TNFSF15rs78486479117569046T>CUpstream variant 2KB
TNFSF15rs78654949117576479C>T
TNFSF15rs42469059114790969T>CIntron variant
TNFSF8rs31813749117665187A>GIntron variant
USP25rs28232562116784706G>AIntron variant
ZMIZ1rs12505691081045207T>CIntron variant
ZMIZ1rs12505461079272775A>GIntron variant
ZNF365rs2241431064477836G>A
rs1145816691663151C>T
LOC105370520rs14954651458016414C>AUpstream variant 2KB
rs107616591064445564A>G
LOC105379031rs7702331573255307A>GIntron variant
rs18193336166960059T>G
LOC105377139rs72824902144195858G>AUpstream variant 2KB
NDUT15rs1863648611348611934G>AMissense
ABCC4rs37655341395815415C>TMissense
AOX1rs3731772212739259T>C
ITPArs1127354203193842C>AIntron variant, missense
MTHFRrs1801133111856378G>AMissense
GSTP1rs16951167585218A>GMissense
RANTES/CCL5rs21075381734207780C>TIntron variant
CCR5rs1799987346411935A>GIntron variant
CCR5rs3181036346412559C>TIntron variant
Supplementary Table 2

SNPs selected for analysis.

No.SNPNo.SNPNo.SNPNo.SNP
1rs100481919rs376553437rs647810855rs1801133
2rs1006517220rs381093638rs760891056rs10883365
3rs1011447021rs51400039rs210753857rs1127354
4rs105300422rs647810940rs318137458rs1250546
5rs1076165923rs214908541rs389432659rs1819333
6rs1119512824rs374917242rs446293760rs2823256
7rs1174186125rs42295143rs495884761rs3731772
8rs1336118926rs728249044rs647810662rs4246905
9rs179996427rs757486545rs751784763rs4574921
10rs200464028rs88820846rs784864764rs72553867
11rs224188029rs1120903247rs786549465rs7702331
12rs320818130rs1123566748rs1123560466rs1487630
13rs380730631rs129205349rs125056967rs1695
14rs440976432rs179998750rs15310968rs1800630
15rs227365033rs426383951rs318103669rs1047266
16rs374563534rs658824852rs1189408170rs10947261
17rs732917435rs690842553rs13003464
18rs776537936rs963787654rs1134986
Supplementary Table 3

Analysis results for 70 SNPs related to CD.

SNPChr.GeneFrequency among the CD groupFrequency among controlsAllelic test P-valueOR95% CI
rs101144709TNFSF150.38340.56561.41E-110.4774(0.3847, 0.5925)
rs38109369TNFSF150.38260.5652.40E-110.4772(0.3835, 0.5938)
rs64781099TNFSF150.37020.53863.55E-100.5035(0.4058, 0.6247)
rs64781089TNFSF150.3740.54253.71E-100.5039(0.4061, 0.6252)
rs42638399TNFSF150.37290.54055.08E-100.5055(0.4072, 0.6277)
rs78486479TNFSF150.37140.53885.11E-100.5059(0.4075, 0.628)
rs42469059TNFSF150.26450.41891.18E-090.4989(0.3981, 0.6252)
rs45749219TNFSF150.26560.41891.55E-090.5015(0.4003, 0.6285)
rs64781069TNFSF150.32490.18274.29E-092.153(1.661, 2.79)
rs112090321IL-23R0.44510.55982.35E-050.6307(0.5091, 0.7814)
rs65882481IL23R0.31190.40660.00026320.6613(0.5293, 0.8263)
rs732917413ELF10.27580.19880.0010741.535(1.186, 1.986)
rs4229516NOTCH40.1460.21150.001250.6374(0.4843, 0.8391)
rs75178471IL23R0.38310.46920.0012570.7025(0.5667, 0.871)
rs133611895IRGM0.50310.42050.00241.395(1.125, 1.73)
rs100651725IRGM0.50.41860.0027391.389(1.12, 1.722)
rs1123560411ATG16L20.13740.086870.0041631.674(1.173, 2.388)
rs88820810NKX2–30.37760.45370.0042940.7304(0.5886, 0.9064)
rs148763044p140.27890.21150.0043791.442(1.12, 1.855)
rs49588475IRGM0.34590.41870.0063740.7342(0.5879, 0.917)
rs96378765IRGM0.49180.41890.0071651.342(1.083, 1.664)
rs1123566711ATG16L2-FCHSD20.13810.090730.0075531.606(1.132, 2.278)
rs117418615ZNF3000.47060.40.008791.333(1.075, 1.654)
rs10048191IL23R0.38420.45140.012170.7584(0.6109, 0.9416)
rs1088336510LINC014750.52280.45540.013471.31(1.057, 1.623)
rs374563519FUT30.17010.12360.017651.454(1.066, 1.982)
rs17999873CCR50.34990.41150.018570.7696(0.6187, 0.9573)
rs1119512810SMNDC1-DUSP50.17240.12690.020951.433(1.055, 1.947)
rs51400018PTPN20.41680.35460.021011.301(1.04, 1.627)
rs440976410NKX2–30.47650.53880.022070.7792(0.6292, 0.9649)
rs109472616BTNL20.3350.2810.032791.289(1.021, 1.628)
rs37491722GPR350.36410.31050.040151.271(1.011, 1.599)
rs15310916IL270.40740.35330.041231.259(1.009, 1.57)
rs77653796MHC0.10680.075290.049071.469(0.9997, 2.159)
rs318137410TNFSF80.4250.47640.063470.8124(0.6523, 1.012)
rs31810363CCR50.1680.20660.06510.7757(0.592, 1.016)
rs105300417STAT30.34760.39230.087070.8255(0.6626, 1.028)
rs69084256CDKAL10.14760.18150.08970.7811(0.587, 1.039)
rs78654949TNFSF150.28790.2490.1091.219(0.9566, 1.554)
rs75748652STAT40.33980.38130.11080.835(0.669, 1.042)
rs130034642PUS100.052150.034750.12691.528(0.8833, 2.644)
rs20046407IRF50.29450.25770.13191.202(0.9459, 1.528)
rs728249021LOC1053771390.4490.48840.14630.8536(0.6894, 1.057)
rs125054610ZMIZ10.42130.45930.160.8571(0.6912, 1.063)
rs129205317TUBD10.44830.48260.20550.8712(0.7038, 1.079)
rs1076165910LOC1053705200.21620.24420.21870.8537(0.6635, 1.099)
rs76089102PUS100.052630.038460.221.389(0.82, 2.353)
rs227365014NFKBIA0.26840.29340.30620.8835(0.6968, 1.12)
rs118940812SOX110.42140.39440.32051.118(0.897, 1.394)
rs125056910ZMIZ10.42870.45350.35840.9044(0.7298, 1.121)
rs282325621LOC1019277450.31260.33590.35980.8992(0.7162, 1.129)
rs22418802ATG16L10.37420.35140.38131.104(0.8845, 1.378)
rs38073067IRF50.18290.1660.41471.125(0.848, 1.491)
rs725538675IRGM0.15960.17570.42370.8908(0.671, 1.183)
rs77023315LOC1053790310.11540.12930.4310.878(0.635, 1.214)
rs11349863DLG10.063020.054050.48781.177(0.7425, 1.866)
rs18011331MTHFR0.29570.27910.50121.085(0.8561, 1.374)
rs389432619FUT30.14470.15640.54670.913(0.6791, 1.228)
rs210753817CCL50.34180.32950.63141.057(0.8432, 1.325)
rs17999646LTA0.17520.18460.64860.9379(0.7117, 1.236)
rs18006306LTA0.15860.16730.66170.938(0.7043, 1.249)
rs21490856RNASET20.39290.38330.71811.041(0.8362, 1.296)
rs10472668TNFRSF10B0.2770.28570.72080.9577(0.7555, 1.214)
rs37317722AOX10.35080.34170.72471.041(0.8319, 1.303)
rs44629373DNAH120.39310.40230.72810.962(0.7735, 1.197)
rs18193336LOC1053790310.39090.38220.74261.037(0.8333, 1.292)
rs112735420ITPA0.17110.16470.75371.047(0.7862, 1.394)
rs32081816HLA-DQA20.12450.11920.76711.05(0.7585, 1.455)
rs169511GSTP10.17650.17120.79411.038(0.7837, 1.375)
rs376553413ABCC40.051830.053850.86760.9605(0.5981, 1.543)

SNPs are ordered according to P values. Chr – chromosome.

Supplementary Table 4

Analysis results for SNPs related to pCD.

NameChr. No.Gene or locusMajor/minor alleleRisk alleleCase RAFControl RAFOR (95% CI)P value alleleP value genotype
rs72553867chr5IRGMC/AA0.1940.1251.685 (1.188–2.390)0.0030.002a
rs4958847chr5IRGMA/GA0.6880.6171.365 (1.047–1.778)0.0210.025c
rs4409764chr10NKX2–3G/TT0.5580.4871.329 (1.033–1.709)0.0270.007a
rs888208chr10NKX2–3A/GA0.6560.5881.338 (1.032–1.735)0.0280.004a
rs3731772chr2AOX1T/CT0.6810.6151.335 (1.025–1.740)0.0320.032a
rs1292053chr17TUBD1G/AA0.4820.4171.300 (1.010–1.674)0.0410.035c
rs3894326chr19FUT3A/TA0.8800.8361.438 (1.001–2.064)0.0490.045c
rs10883365chr10NKX2–3A/GG0.5480.4961.234 (0.957–1.590)0.1050.033a
rs3181374chr9TNFSF8A/GA0.6870.6421.226 (0.939–1.600)0.1350.069a
rs11235667chr11ATG16L2-FCHSD2A/GA0.8770.8441.314 (0.914–1.887)0.1390.148c
rs3749172chr2GPR35C/AA0.3870.3431.209 (0.926–1.577)0.1620.055b
rs2241880chr2ATG16L1A/GG0.3940.3551.185 (0.915–1.534)0.1990.182b
rs153109chr16IL27T/CT0.6130.5731.181 (0.914–1.526)0.2040.094a
rs1800630chr6TNFC/AC0.8570.8281.242 (0.881–1.752)0.2160.168b
rs11235604chr11ATG16L2C/TC0.8750.8481.256 (0.873–1.805)0.2190.225c
rs7282490chr21ICOSLGG/AA0.4680.4291.168 (0.907–1.504)0.2280.205b
rs2107538chr17CCL5C/TT0.3600.3251.168 (0.897–1.522)0.2490.239c
rs10114470chr9TNFSF15C/TC0.6330.5981.160 (0.897–1.500)0.2590.128a
rs514000chr18PTPN2T/CT0.6000.5641.160 (0.895–1.501)0.2620.106a
rs11209032chr1IL23R-IL12RB2A/GG0.4640.4291.149 (0.893–1.478)0.2810.275a

SNPs are ordered according to P values.

p value for the dominant model;

p value for the regressive model;

p value for the additive model.

Chr – chromosome; RAF – risk allele frequency

Supplementary Table 5

Logistic analysis results for SNPs related to pCD.

Risk alleleUnivariateMultivariate
OR (95% CI)P valueOR (95% CI)P value
rs72553867aAC+AA vs. CC1.874 (1.246–2.817)0.0031.770 (1.151–2.723)0.009
rs4958847cA vs. G1.366 (1.045–1.786)0.023
rs4409764aGT+TT vs. GG1.780 (1.149–2.758)0.0101.886 (1.181–3.012)0.008
rs888208aAG+AA vs. GG2.087 (1.205–3.616)0.009
rs3731772aT C+TT vs. CC1.941 (1.099–3.428)0.0222.131 (1.150–3.949)0.016
rs1292053aAG+AA vs. GG1.487 (0.992–2.230)0.055
rs3894326cA vs. T1.380 (0.943–2.017)0.097
Age (year)//0.968 (0.951–0.984)<0.001
Male/Female//1.608 (1.059–2.442)0.026

Dominant model;

additive model.

  42 in total

1.  Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study.

Authors:  Zhirong Zeng; Zhenhua Zhu; Yuyu Yang; Weishan Ruan; Xiabiao Peng; Yuhuan Su; Lin Peng; Jinquan Chen; Quan Yin; Chao Zhao; Haihua Zhou; Shuai Yuan; Yuantao Hao; Jiaming Qian; Siew Chien Ng; Minhu Chen; Pinjin Hu
Journal:  J Gastroenterol Hepatol       Date:  2013-07       Impact factor: 4.029

2.  Association of IL23R and ATG16L1 with susceptibility of Crohn's disease in Chinese population.

Authors:  Jie Zhang; Jiebin Chen; Jianjun Gu; Huimin Guo; Weichang Chen
Journal:  Scand J Gastroenterol       Date:  2014-07-22       Impact factor: 2.423

3.  TNFSF15 is an independent predictor for the development of Crohn's disease-related complications in Koreans.

Authors:  Dong-Hoon Yang; Suk-Kyun Yang; Kyuyoung Song; Myunghee Hong; Sang Hyoung Park; Ho-Su Lee; Ji-Beom Kim; Hyo Jeong Lee; Soo-Kyung Park; Kee Wook Jung; Kyung-Jo Kim; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Jin-Ho Kim; Ui Sup Shin; Chang Sik Yu; Inchul Lee
Journal:  J Crohns Colitis       Date:  2014-05-14       Impact factor: 9.071

4.  Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study.

Authors:  Jochen Hampe; Jochen Grebe; Susanna Nikolaus; Camilla Solberg; Peter J P Croucher; Silvia Mascheretti; Jörgen Jahnsen; Björn Moum; Bodo Klump; Michael Krawczak; Muddassar M Mirza; Ulrich R Foelsch; Morten Vatn; Stefan Schreiber
Journal:  Lancet       Date:  2002-05-11       Impact factor: 79.321

5.  3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.

Authors:  Fernando Gomollón; Axel Dignass; Vito Annese; Herbert Tilg; Gert Van Assche; James O Lindsay; Laurent Peyrin-Biroulet; Garret J Cullen; Marco Daperno; Torsten Kucharzik; Florian Rieder; Sven Almer; Alessandro Armuzzi; Marcus Harbord; Jost Langhorst; Miquel Sans; Yehuda Chowers; Gionata Fiorino; Pascal Juillerat; Gerassimos J Mantzaris; Fernando Rizzello; Stephan Vavricka; Paolo Gionchetti
Journal:  J Crohns Colitis       Date:  2016-09-22       Impact factor: 9.071

6.  Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation.

Authors:  John L Prehn; Shahab Mehdizadeh; Carol J Landers; Xia Luo; Stephanie C Cha; Ping Wei; Stephan R Targan
Journal:  Clin Immunol       Date:  2004-07       Impact factor: 3.969

7.  MDR1 Ala893 polymorphism is associated with inflammatory bowel disease.

Authors:  Steven R Brant; Carolien I M Panhuysen; Dan Nicolae; Deepthi M Reddy; Denise K Bonen; Reda Karaliukas; Leilei Zhang; Eric Swanson; Lisa W Datta; Thomas Moran; Geoffrey Ravenhill; Richard H Duerr; Jean-Paul Achkar; Amir S Karban; Judy H Cho
Journal:  Am J Hum Genet       Date:  2003-11-07       Impact factor: 11.025

Review 8.  Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease.

Authors:  Arthur Kaser; Richard S Blumberg
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

9.  Analysis of the association of single nucleotide polymorphisms of interleukin-23 receptor (IL-23R) and inflammatory bowel disease in a Chinese Han cohort.

Authors:  Zhong-Kai Lu; Zhi-Rong Chen; Jun-Yi Zhu; Ya Xu; Xian Hua
Journal:  Oncotarget       Date:  2016-10-18

10.  Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.

Authors:  Isabelle Cleynen; Gabrielle Boucher; Luke Jostins; L Philip Schumm; Sebastian Zeissig; Tariq Ahmad; Vibeke Andersen; Jane M Andrews; Vito Annese; Stephan Brand; Steven R Brant; Judy H Cho; Mark J Daly; Marla Dubinsky; Richard H Duerr; Lynnette R Ferguson; Andre Franke; Richard B Gearry; Philippe Goyette; Hakon Hakonarson; Jonas Halfvarson; Johannes R Hov; Hailang Huang; Nicholas A Kennedy; Limas Kupcinskas; Ian C Lawrance; James C Lee; Jack Satsangi; Stephan Schreiber; Emilie Théâtre; Andrea E van der Meulen-de Jong; Rinse K Weersma; David C Wilson; Miles Parkes; Severine Vermeire; John D Rioux; John Mansfield; Mark S Silverberg; Graham Radford-Smith; Dermot P B McGovern; Jeffrey C Barrett; Charlie W Lees
Journal:  Lancet       Date:  2015-10-18       Impact factor: 202.731

View more
  2 in total

Review 1.  A Review on Inflammatory Bowel Diseases: Recent Molecular Pathophysiology Advances.

Authors:  Maheeba Abdulla; Nafeesa Mohammed
Journal:  Biologics       Date:  2022-09-12

2.  Cell Type-Specific Induction of Inflammation-Associated Genes in Crohn's Disease and Colorectal Cancer.

Authors:  Dominik Saul; Luísa Leite Barros; Alexander Q Wixom; Benjamin Gellhaus; Hunter R Gibbons; William A Faubion; Robyn Laura Kosinsky
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.